Feature Stock: Avalon GloboCare crossed the 20 SMA and bounced of the 50 SMA. We are looking for this to make another run at the 50 and break through. MACD has curled up and about to cross…

Biotechnology, Cannabis Stocks, Commodities and Mining Stocks, Energy and Technology, Our Research
March 21, 2022
A+ A-
Email Print
The New Oncology Platform Being Developed at Avalon GloboCare (NASDAQ: AVCO) is Separating Them from Their Peers

Good day everyone,

AVCO crossed the 20 SMA and bounced of the 50 SMA. We are looking for this to make another run at the 50 and break through. MACD has curled up and about to cross.

Avalon GloboCare Corp. (NASDAQ: AVCO) Update

AVCO shares on the move and gaining momentum up 11.56% in early trading today on traded volume of over 200K shares at 10:10 AM EST. Opening price was .66/share.

Current price $.75/share (at 10:10 am EST 3-21-22)

AVA-011 is AVCO’s lead CAR-T candidate, and part of the Company’s proprietary mRNA-based FLASH-CAR™ platform. The work going now, augmenting the platform with CAR-NK cell is a major development for the company. AVCO’s work to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors could be a significant oncology treatment breakthrough.

As I mentioned earlier, AVA-011 is currently at the IND-enabling process development stage and the company hopes to be in human clinical trials in Q2/Q3 this year. The recent appointment of Dr. Dongfang Liu to the AVCO Scientific and Clinical Advisory Board, with over 20 years’ experience developing CAR-NK cells, may expedite the FDA process.

Stay tuned for the full report on AVCO coming soon.

The Traders News Group
original report below

Avalon GloboCare (AVCO) has an (mRNA)-based technology platform and we could see an IND application any day now.

Promising Tech With An Ideal Swing Setup. See the chart below.

Good day everyone,

Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage CellTech bio-developer involved in advanced oncology therapies. Their CAR-T technology will remove cells from a cancer patient’s body, modify them and introduce the modified cancer fighting cells back into the patient.

Current price $.6723/share (as of market close 3-18-22)

AVCO is focused on advancing their immune effector cell therapies, including CAR-T and CAR-NK, their S-layer coated emulsome technology (SLET), their exosome-based regenerative therapeutics (ACTEX™), as well as their liquid biopsy diagnostic and drug delivery platforms. The AVCO website is an excellent source of info on their technology.

AVCO’s lead candidate, AVA-011, combines Avalon’s FLASH-CAR™ technology with an innovative messenger ribonucleic acid (mRNA)-based technology platform, and is currently at an IND-enabling stage. Avalon is on track to initiate AVA-011 first-in-human clinical trial by mid-2022. The company anticipates their technology can modify cells quicker (days not weeks) and cheaper than other CAR-T therapies.

Dr. David Jin, President and CEO has said, “As we head further into 2022, we believe we have a number of important upcoming milestones that have the potential to drive significant value for our shareholders.”

AVCO statistics:

FYE is 12-31 – Outstanding shares 88.4M – Float 33.3M shares – Insider ownership is 62.9% – 52-week high is $1.57/share – Market cap $59M – Recent high (2-14-22) $.94/share – Revenues of $1.45M (ttm)

I encourage you to view this video interview with David Jin, M.D., Ph.D. CEO and President of AVCO. I found it to be informative and interesting as Dr. Jin lays out the potentials for success in the AVCO oncology cell technologies and discusses how their mRNA CAR-T candidate AVA-011 is superior to conventional CAR-T therapies.

As indicated in the chart below, AVCO shares experienced a wide range last week, as the NASDAQ rallied, trading between $.58 and $.75/share. Given the developments I detail below and the current soft RSI (14) of 42.36, I can see where AVCO shares could bounce past the MA50 of $.75 quickly and may cross the MA200 of $.92 in the near term. To me, this chart indicates a good potential swing in the works.

AVCO posted revenues of $1.45M (ttm) as of their last reporting for Q321 (FYE is 12-31) and I want to note that Q321 was their strongest performance in 2021 coming in at $486K revenues. I expect AVCO to update their earning report in the next few weeks.

Recent developments at AVCO:

In late December, the company’s Chairman, Daniel Lu, converted $3.0 million of debt owed to him under the company Line of Credit into 2.4 million shares of the Company’s common stock at $1.25 per share. The conversion price was at a 45% premium to the share price at the time. That move indicates Mr. Lu’s confidence in the company.

Last year the company announced that it planned to acquire SenlangBio, a company that had initiated a first-in-human clinical trial evaluating anti-EphA2 chimeric antigen receptor (CAR) T-cell therapy for recurrent glioblastoma. The all-stock transaction was going to be for 81M AVCO common shares, a significant dilution for shareholders. In Q122 the company announced it had cancelled the planned acquisition citing the significant dilution to shareholders. Good news for investors today as I believe the company value had already reflected the dilution.

Let’s compare AVCO with other NASDAQ development stage companies in the oncology sector that are absent revenues:

BriaCell Therapeutics Corp. (BCTX) Market Value $137M

ALX Oncology Holdings Inc. (ALXO) Market Value $812M

Avalon GloboCare Corp. (AVCO) Market Value $59M

PDS Biotechnology Corporation (PDSB) Market Value $189M

I note in making the comparisons above that AVCO is revenue positive.

AVCO Development Highlights:

Avalon entered a new collaboration with University of Pittsburgh Medical Center (UPMC) to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring these powerful treatments to cancer patients with a rapid bio-manufacturing time (1-2 days instead of weeks). Avalon’s lead candidate, AVA-011, combines Avalon’s FLASH-CAR™ technology with an innovative messenger ribonucleic acid (mRNA)-based technology platform, and is currently at an IND-enabling stage. Avalon is on track to initiate AVA-011 first-in-human clinical trial by mid-2022.

Avalon has co-developed and jointly filed a patent with BOKU on a novel platform of S-layer coated emulsome technology (SLET) for next-generation, targeted drug delivery and cellular immunotherapy applications. The Company believes this novel SLET platform will help accelerate the development of Avalon’s mRNA-based Flash-CAR™ and other cellular therapy programs. Targeted delivery of mRNA into immune effector cells using SLET can potentially open the door to new generation of cancer immunotherapy and other applications including targeted drug delivery and therapeutics, vaccine development, in vitro diagnostics, and cellular medicines.

The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon’s lead CAR-T candidate, part of the Company’s proprietary mRNA-based FLASH-CAR™ platform. AVA-011 is currently at the IND-enabling, process development stage, which is expected to produce clinical-grade CAR-T cells for an upcoming clinical trial in patients with hematological malignancies. The platform uses next generation CAR technology to modify patients’ T or universal-donor NK cells using a ribonucleic acid (RNA)-based platform rather than a viral vector, allowing for more rapid and lower-cost bio-manufacturing of the cell therapy products.

To further strengthen its CAR-NK development capabilities, Avalon has appointed Dr. Dongfang Liu to its Scientific and Clinical Advisory Board. Dr. Liu is currently an Associate Professor and Director of Immunoassay Development Program at the Department of Pathology, Immunology and Laboratory Medicine at The Rutgers University New Jersey Medical School. Dr. Liu’s research expertise is focused on the immunobiology of NK and CAR-NK, with more than 20 years of experience in NK cell research.

About Avalon GloboCare Corp: AVCO is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.

Updates and full report on AVCO coming soon,

The Traders News Group
Privacy Policy and Disclaimer

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We do not sell your information to anyone. Please see our cookie policy below.

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.

What do we use your information for?

When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.

We send periodic emails

The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.

Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.

Online Privacy Policy Policy

This online privacy policy applies to information collected through our website and social media platforms.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.

Editor@TradersNewsSource.com

Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated twenty four thousand dollars cash via bank wire for our distributed opinions this week (3-21-22 through 3-22-22) on avco. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.

TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.

Posted by

Newer Post
Older Post